Oncomine portfolio expansion

Thermo Fisher Scientific expands Oncomine immuno-oncology assay portfolio with TCR Beta-SR Assay

Register for free to listen to this article
Listen with Speechify
CARLSBAD, Calif.—Thermo Fisher Scientific has announced the launch of its new Oncomine TCR Beta-SR Assay, a next-generation sequencing (NGS) solution for immuno-oncology research which is designed to characterize T cell clonality in the tumor microenvironment - a key approach to identify potential biomarkers associated with immune response. The latest addition to the Oncomine product portfolio is being featured at the European Association of Cancer Research (EACR25) conference (booth #53-54) in Amsterdam, Netherlands, June 30 - July 3, when the company will also host a symposium featuring customer presentations on the latest advancements in immuno-oncology and liquid biopsy clinical research.
Scientists believe that harnessing the power of T cell receptor diversity through a targeted sequencing approach provides the highest level of resolution to help identify predictive and prognostic biomarkers associated with cancer immunotherapy, monitor toxicity, treatment resistance and optimize the manufacture and function of therapeutic T-cells. Oncomine TCR Beta-SR Assay is designed to specifically interrogate the CDR3 region of the beta chain of the T cell receptor, a region that is responsible for antigen recognition and important in uniquely identifying T cell clones.
The assay’s utilization of dual barcode indexing also enables identification of low-frequency clones which has the potential for tracking minimal residual disease. Interrogation of data obtained with the Oncomine TCR Beta-SR Assay (SR = Short Read) is optimized for formalin-fixed paraffin-embedded (FFPE), peripheral blood leukocytes (PBL), peripheral blood mononuclear cells (PBMC) or cell-free DNA (cfDNA) samples.
A unique feature of Oncomine TCR Beta-SR Assay design is its flexibility for translational researchers to use either DNA or RNA input without interference from primer bias while returning results within 48 hours on the Ion GeneStudio S5 Series instruments and Ion Torrent analysis solutions. When coupled with the Oncomine TCR Beta-LR Assay (LR = Long Read), researchers can achieve a comprehensive range of TCR beta sequencing applications, including TRBV allele typing, clonality association to immune response and engineered T cell monitoring.
“TCR sequencing is an essential tool for fingerprinting T-cell responses in cancer,” said Noel de Miranda, Ph.D., department of Pathology, Leiden University Medical Center, Leiden, Netherlands. “The Oncomine TCR Beta-LR Assay excels by delivering the full CDR sequences in a single sequencing read. We are currently applying it for the characterization of neo-antigen-specific T-cells and for the improvement of immunotherapeutic modalities.”
Thermo Fisher’s symposium during EACR25 will feature key customer thought leaders and scientists in immuno-oncology and liquid biopsy research. The symposium begins at 1 pm on July 1 at the RAI Conference Center in Room G103.
Topics and speakers will include:
“Current practice, needs and future directions immuno-oncology research testing,” by Professor
Jose Carlos Machada, Ph.D., Board of Directors member and Group Coordinator, IPATIMUP,
Porto, Portugal.
“Fingerprinting immune responses and improving immunotherapies with TCR sequencing,” by
Noel de Miranda, Ph.D., department of Pathology, Leiden University Medical Center, Leiden,
“Liquid biopsies sensitive detection in cfDNA in breast and lung,” by Professor Jacqui Shaw,
Ph.D., Leicester Cancer Research Centre, Leicester, UK.
“An Innovative multi-dimensional NGS approach to understanding the tumor microenvironment
and evolution,” by Jim H. Godsey, Ph.D., Vice President, R&D Clinical Sequencing at Thermo
Fisher Scientific.

Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

DDN Magazine May 2024

Latest Issue  

• Volume 20 • Issue 3 • May 2024

May 2024

May 2024 Issue